
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health Inc. is experiencing robust subscriber growth, particularly in the weight-loss sector, with a reported 70% year-over-year increase in subscribers in Q4, which bodes well for sequential revenue growth into subsequent quarters. The company's diversification into various healthcare specialties has mitigated concentration risk, ensuring resilience in its revenue streams, even as it capitalizes on growth in the GLP-1 market. Additionally, strategic partnerships and new product offerings position Hims & Hers to leverage future sales in emerging weight-loss medications, further enhancing its positive growth outlook through 2026.
Bears say
Hims & Hers Health Inc. faces a negative outlook primarily due to significantly slowing revenue growth, as indicated by disappointing 4Q:25 earnings and weak revenue guidance for 1Q:26. The company's full-year 2026 revenue estimate has been revised downward, projecting between $2.7 billion and $2.9 billion, which is lower than previous expectations and highlights concerns about sustained growth. Additionally, increased legal and regulatory risks contribute to the negative sentiment surrounding the stock, as the latest financial metrics indicate a decline in both revenue and EBITDA forecasts for 2027.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares